---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-019854"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:14:15.383646+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q4 revenue $165M, FY $560M; guides 2025 revenue $640-670M

## Summary
- Q4 2024 total revenue $165M (+29% YoY); FY 2024 total revenue $560M (+29% YoY).
- Crysvita FY revenue $410M (+25% YoY); Dojolvi FY revenue $88M (+25% YoY).
- FY 2024 net loss $569M ($6.29/diluted share) vs $607M ($8.25) in 2023; cash used ops $414M.
- 2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M; lower cash ops expected.
- PDUFA decision for UX111 gene therapy (Sanfilippo syndrome) expected H2 2025; BLA filing for DTX401 (GSDIa) mid-2025.

## SEC filing metadata
- accession: 0000950170-25-019854
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/0000950170-25-019854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/rare-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-019854
- JSON: https://secwatch.observer/filing/0000950170-25-019854.json
- Plain text: https://secwatch.observer/filing/0000950170-25-019854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.